T1ρ-based dynamic glucose-enhanced (DGEρ) MRI at 3 T: method development and early clinical experience in the human brain.


Journal

Magnetic resonance in medicine
ISSN: 1522-2594
Titre abrégé: Magn Reson Med
Pays: United States
ID NLM: 8505245

Informations de publication

Date de publication:
11 2019
Historique:
received: 12 02 2019
revised: 17 04 2019
accepted: 21 05 2019
pubmed: 25 6 2019
medline: 20 6 2020
entrez: 25 6 2019
Statut: ppublish

Résumé

The aim of this study was to translate the T Spin-lock based presaturation and a 3D gradient-echo snapshot readout were optimized for 3 T with regard to robustness, chemical exchange saturation transfer effect strength, and SNR. Postprocessing steps, including dynamic B With appropriate postprocessing, motion-related artifacts could be drastically reduced, and an SNR of approximately 90 could be achieved for a single dynamic measurement. In 2 patients with blood-brain barrier breakdown, a significant glucose uptake could be observed with a DGEρ effect strength in the range of 0.4% of the water signal. Thorough analysis of possible residual motion revealed that the statistical evidence can decrease when tested against pseudo effects attributed to uncorrected motion. DGEρ imaging was optimized for clinical field strengths of 3 T, and a robust protocol was established for broader application. Early experience shows that DGEρ seems possible at 3 T and could not only be attributed to motion artifacts. Observed DGEρ maps showed unique patterns, partly matching with the T

Identifiants

pubmed: 31231853
doi: 10.1002/mrm.27857
doi:

Substances chimiques

Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1832-1847

Informations de copyright

© 2019 International Society for Magnetic Resonance in Medicine.

Auteurs

Kai Herz (K)

Magnetic Resonance Center, Max Planck Institute for Biological Cybernetics, Tübingen, Germany.
IMPRS for Cognitive and Systems Neuroscience, University of Tübingen, Tübingen, Germany.

Tobias Lindig (T)

Magnetic Resonance Center, Max Planck Institute for Biological Cybernetics, Tübingen, Germany.
Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Tübingen, Germany.

Anagha Deshmane (A)

Magnetic Resonance Center, Max Planck Institute for Biological Cybernetics, Tübingen, Germany.

Jens Schittenhelm (J)

Department of Neuropathology, University Hospital Tübingen, Tübingen, Germany.

Marco Skardelly (M)

Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.

Benjamin Bender (B)

Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Tübingen, Germany.

Ulrike Ernemann (U)

Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Tübingen, Germany.

Klaus Scheffler (K)

Magnetic Resonance Center, Max Planck Institute for Biological Cybernetics, Tübingen, Germany.
Department of Biomedical Magnetic Resonance, University Hospital Tübingen, Tübingen, Germany.

Moritz Zaiss (M)

Magnetic Resonance Center, Max Planck Institute for Biological Cybernetics, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH